Management of Defecatory (Dyssynergic) Disorders

Fluid and Fiber Recommendations

• In adults with chronic constipation, daily fluid intake above 1.5–2 L does not provide additional benefit; only individuals in the lowest quartile of intake experience improvement, so consuming > 2 L (e.g., 4 L) offers no extra advantage. American Gastroenterological Association recommendation. 1
• High‑dose fiber (e.g., large servings of spinach) can worsen outlet obstruction in dyssynergic defecation because increased stool bulk cannot be expelled; the American Gastroenterological Association advises against high‑dose fiber in this subtype. 1
• For patients with short‑bowel syndrome or malabsorption, foods high in oxalate such as spinach should be avoided to reduce the risk of calcium‑oxalate renal stones. Gut Society guidance. 2

Diagnostic Work‑up

• Initial laboratory evaluation should be limited to a complete blood count to rule out anemia; routine metabolic panels (glucose, calcium, TSH) are not recommended unless clinically indicated because their diagnostic yield is extremely low. American Gastroenterological Association. 1
• Anorectal manometry combined with a balloon expulsion test must be performed before colonoscopy or colonic transit studies when a defecatory disorder is suspected. Failure to expel a 50 mL water‑filled balloon within 1–3 minutes confirms dyssynergia. American Gastroenterological Association. 1
• If manometry and balloon tests are discordant, add fluoroscopic or MR defecography to visualize pelvic‑floor dynamics and detect structural abnormalities (e.g., rectocele, intussusception). American Gastroenterological Association. 1

Immediate (First‑Week) Management

• Discontinue ineffective interventions: reduce oral hypotonic fluid intake to ≈ 500 mL/day (principle derived from jejunostomy patient data) and avoid high‑dose fiber or bulk laxatives until normal pelvic‑floor function is confirmed. Gut Society and American Gastroenterological Association. [2][1]
• Medication review is mandatory: opioids, anticholinergics, calcium‑channel blockers, iron supplements, and certain antidepressants are known constipating agents; discontinue all non‑essential constipating medications. National Comprehensive Cancer Network (NCCN). 3

Pharmacologic Therapy

• Polyethylene glycol (PEG) 17 g daily is strongly recommended with moderate certainty of evidence for softening stools in dyssynergic constipation. American Gastroenterological Association (Grade A). 1
• If constipation persists, add bisacodyl 10–15 mg 2–3 times daily as a stimulant laxative. NCCN guidance. 3
• Treatment goal: achieve one non‑forced bowel movement every 1–2 days. NCCN. 3

Definitive Therapy

• Biofeedback therapy is the first‑line definitive treatment for dyssynergic defecation, carrying a Grade A recommendation and a 70–80 % success rate. Typical protocol: 4–6 sessions over 8–12 weeks with a trained pelvic‑floor therapist. Predictors of success include lower baseline rectal sensory thresholds and absence of depression. American Gastroenterological Association. 1

Common Pitfalls to Avoid

• Do not prescribe additional fiber or water without first identifying the constipation subtype; fiber is appropriate only for mild constipation with low baseline intake, and it may exacerbate symptoms in defecatory disorders. American Gastroenterological Association. 1
• Do not order colonic transit studies before completing anorectal testing, as up to one‑third of patients have secondary colonic slowing secondary to untreated dyssynergia; treating the outlet obstruction first can normalize transit. American Gastroenterological Association. 1
• Do not proceed to surgical interventions without confirming normal anorectal function, because unrecognized dyssynergia can lead to poor surgical outcomes. American Gastroenterological Association. 1

Referral Recommendations

• Refer to gastroenterology or a pelvic‑floor specialist for anorectal manometry, balloon expulsion testing, and biofeedback therapy when dyssynergic defecation is suspected or refractory. American Gastroenterological Association. 1
• Refer to colorectal surgery if defecography reveals structural pelvic‑floor abnormalities requiring repair or if true slow‑transit constipation persists after exhaustive medical management. American Gastroenterological Association. 1

Constipation Causes and Management

Primary Causes

• Constipation is primarily caused by disordered colonic and/or pelvic floor/anorectal function, which can be categorized into defecatory disorders, normal transit constipation (NTC), and slow transit constipation (STC) 4, 5, 6
• Defecatory disorders are characterized by impaired rectal evacuation due to inadequate rectal propulsive forces and/or increased resistance to evacuation 4, 5
• Defecatory disorders may result from high anal resting pressure and/or incomplete relaxation or paradoxical contraction of the pelvic floor and external anal sphincters during defecation 5, 6
• Normal transit constipation (NTC) is characterized by normal anorectal function with normal colonic transit 5
• Slow transit constipation (STC) is characterized by normal anorectal function with slow colonic transit 6
• Some patients with STC have reduced colonic propulsive activity or increased uncoordinated motor activity in the distal colon 4
• Resected colonic specimens from patients with STC reveal marked reduction in colonic intrinsic nerves and interstitial cells of Cajal 5
• Abnormal colonic sensation has been described in chronic constipation 6

Secondary Causes

• Opioid analgesics cause constipation with no development of tolerance over time 7
• Opioids inhibit intestinal motility by activating enteric μ-receptors, resulting in increased tonic non-propulsive contractions, increased colonic fluid absorption, and stool desiccation 8
• Other medications associated with constipation include anticholinergics, calcium channel blockers 9
• Diseases of the colon, such as stricture, cancer, anal fissure, and proctitis, can cause constipation 5
• Metabolic disturbances, such as hypercalcemia, hypokalemia, hypothyroidism, diabetes mellitus, and uremia, can contribute to constipation 5, 7
• Neurologic disorders, such as Parkinsonism and spinal cord lesions, can cause constipation 5
• Radiation damage can cause strictures and/or generalized secondary dysmotility 9, 10
• Abdominal or pelvic masses can cause constipation 7

Clinical Presentation and Diagnostic Clues

• Constipation manifests with various symptoms, including infrequent bowel movements, straining during defecations, lumpy or hard stools, sensation of incomplete evacuation, and sensation of anorectal obstruction/blockage 8
• Prolonged and excessive straining before elimination suggests defecatory disorders 5
• Difficulty passing soft stools or enema fluid indicates pronounced evacuatory defects 6
• Need for perineal or vaginal pressure to allow stool passage or direct digital evacuation strongly suggests defecatory disorders 4
• Distinct transition point between dilated and normal sized bowel on imaging suggests organic obstruction 10
• Visible small bowel peristalsis, worse pain after prokinetic drugs, or giant jejunal contractions on manometry suggest organic obstruction 9

Management Considerations

• For opioid-induced constipation, peripherally acting μ-opioid receptor antagonists (PAMORAs) like methylnaltrexone can provide relief while preserving pain management 11
• For constipation in Parkinson's disease, fermented milk containing probiotics and prebiotic fiber can be beneficial 12